BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

University of Amsterdam Joins the MetaMiner Metabolic Diseases Project


2/22/2010 8:33:07 AM

ST. JOSEPH, Mich., Feb. 22 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that the Medical Biochemistry group at the Academic Medical Center, University of Amsterdam will join the MetaMiner Metabolic Diseases project from GeneGo. The MetaMiner program is focused on the fundamental understanding of human diseases at the level of disease pathways and causative gene-disease associations supported by a repository of OMICs data. Ongoing MetaMiner projects include Oncology, CNS, Cystic fibrosis and Stem cells.

"The University of Amsterdam group is well known for their research on nutrition and fasting and we really welcome Milka's expertise in this area," said Julie Bryant, GeneGo's VP of Business Development. "This will be the first 'systems analysis' platform devoted specifically for metabolic diseases. We will start with the 'usual suspects' of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism."

For more information, please visit the company's web site at www.genego.com.

CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, julie@genego.com

Web site: http://www.genego.com/


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->